Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ESC Congress 2004: New findings from ground-breaking PROVE IT-TIMI 22 clinical trial

31.08.2004


Study finds antibiotics do not prevent heart attacks



Results from landmark PROVE IT-TIMI 22 trial suggest clinicians should use proven therapies, such as high-dose statin therapy, to reduce cardiovascular disease risk factors.

Previous studies have found Chlamydia pneumoniae, a common bacterium that causes respiratory illness, may also be a risk factor for atherosclerosis and other cardiovascular diseases. Researchers and clinicians had hoped that treating C. pneumoniae with antibiotics would kill the bacterium and therefore reduce the risk of cardiac events. However, in the landmark PROVE IT-TIMI 22 clinical trial, researches from Brigham and Women’s Hospital (BWH) and colleagues found that even a long-term regimen of antibiotics designed to kill C. pneumoniae does not reduce heart attacks or cardiovascular disease risk. Clinicians instead should continue to focus on other methods to reduce risk factors such as high-dose statins and ACE inhibitors.


Commenting from the European Society of Cardiology meeting, lead investigator of the PROVE IT – TIMI 22 trial (Pravastatin or Atorvastatin Evaluation and Infection Therapy), Christopher P. Cannon, MD of the TIMI Study Group in the Cardiovascular Division of BWH and associate professor of Medicine at Harvard Medical School (HMS) said, "This portion of the PROVE IT-TIMI 22 trial looked at the impact of full-dose, long-term use of antibiotics but found they did not prevent heart attacks. Clinicians need to use proven therapies to treat heart disease risk, including high-dose statins, found to be effective in the statin component of the PROVE IT trial."

PROVE IT enrolled 4,162 patients hospitalized within 10 days for an acute coronary syndrome. Approximately half the patient population was administered the antibiotic Gatifloxacin and the other half was administered a placebo, each for a 10-day course per month over a period of two years. Researchers found that those who participated in the antibiotic therapy had the same risk of a cardiac event as their placebo therapy counterparts.

"While there have been great strides in addressing cardiovascular diseases, a regimen of antibiotics does not appear to be effective in reducing coronary risk," said Eugene Braunwald, MD, chairman of the TIMI Study Group at BWH and HMS professor.

In addition to the antibiotic portion of the trial, PROVE IT-TIMI 22 is the first major comparison of clinical outcomes of two statin drugs. Earlier this year, researchers announced they had found a greater reduction in death or major cardiac events with more intensive lowering of cholesterol and, for patients who have recently suffered an acute coronary syndrome (ACS), they had greater protection from death and other cardiac events after treatment with a high-dose statin therapy, as compared to a standard-dose. Bristol-Myers Squibb and Sankyo funded this study. BWH is a 735-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare System, an integrated health care delivery network. Internationally recognized as a leading academic health care institution, BWH is committed to excellence in patient care, medical research, and the training and education of health care professionals. The hospital’s preeminence in all aspects of clinical care is coupled with its strength in medical research. A leading recipient of research grants from the National Institutes of Health, BWH conducts internationally acclaimed clinical, basic and epidemiological studies. CP Cannon (Boston, US)

Camilla Dormer | EurekAlert!
Further information:
http://www.escardio.org

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Solar Collectors from Ultra-High Performance Concrete Combine Energy Efficiency and Aesthetics

16.01.2017 | Trade Fair News

3D scans for the automotive industry

16.01.2017 | Automotive Engineering

Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs

16.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>